TGFB1 and metabolic dysfunction-associated steatohepatitis: More recently, we have discovered a semi-synthetic proprietary oxysterol, Oxy210 (Figure 1), which is similar to Oxy186 in potently inhibiting Hh signaling but also is a potent inhibitor of transforming growth factor-beta (TGF-β)-mediated responses in fibroblastic cells and A549 non-small cell lung cancer cells [36], and in human hepatic stellate cells (HSC), with relevance in both fibrosis-driven cancers and chronic fibrotic diseases, such as non-alcoholic steatohepatitis (NASH) [37].